OTLK
Outlook Therapeutics, Inc. NASDAQ Listed Jun 14, 2016$0.22
After hrs
$0.23
+2.17%
Mkt Cap $8.9M
52w Low $0.16
1.7% of range
52w High $3.39
50d MA $0.31
200d MA $1.09
P/E (TTM)
-0.1x
EV/EBITDA
-0.9x
P/B
—
Debt/Equity
-0.9x
ROE
266.8%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
0.19
50d MA
$0.31
200d MA
$1.09
Avg Volume
3.1M
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Building F · Iselin, NJ 08852 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | -0.17 | -0.22 | -29.4% | 0.42 | +1.0% | -3.0% | +6.1% | -4.9% | -3.2% | +2.8% | — |
| Dec 19, 2025 | AMC | -0.26 | -0.22 | +15.4% | 2.01 | +1.0% | -8.5% | +1.1% | -1.6% | -0.5% | +8.8% | — |
| Aug 14, 2025 | AMC | -0.42 | -0.44 | -4.8% | 2.43 | +2.9% | -3.7% | +18.4% | -5.1% | -9.1% | +0.8% | — |
| May 15, 2025 | AMC | -0.55 | -0.40 | +27.3% | 1.68 | +1.2% | +4.2% | +0.6% | -3.4% | -4.1% | +0.6% | — |
| Feb 14, 2025 | AMC | -0.85 | -0.89 | -4.7% | 1.87 | -1.1% | -8.6% | -0.6% | -3.5% | -4.9% | -2.6% | — |
| Dec 27, 2024 | AMC | -0.83 | -0.77 | +7.2% | 2.01 | -2.0% | -7.5% | +1.6% | +9.0% | +8.7% | +5.8% | — |
| Aug 14, 2024 | AMC | -1.06 | -0.83 | +21.7% | 7.34 | +1.5% | +4.6% | +0.4% | -7.1% | -0.8% | +2.4% | — |
| May 15, 2024 | AMC | -0.88 | -1.55 | -76.1% | 7.43 | -3.9% | -1.3% | +6.1% | +2.2% | -1.0% | +1.7% | — |
| Feb 14, 2024 | AMC | -1.00 | -0.80 | +20.0% | 8.41 | +7.0% | +15.3% | -6.9% | -3.9% | -3.7% | +2.6% | — |
| Dec 22, 2023 | AMC | -1.00 | -1.00 | +0.0% | 8.46 | +1.7% | +5.4% | +3.7% | -7.8% | -7.6% | -0.3% | — |
| Aug 14, 2023 | AMC | -0.80 | -1.60 | -100.0% | 31.40 | +1.9% | -1.3% | -12.3% | +4.8% | -6.7% | +3.0% | — |
| May 15, 2023 | AMC | -1.20 | -0.60 | +50.0% | 24.00 | -0.8% | -0.8% | +0.8% | +1.7% | +9.8% | +21.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.45 | $0.45 | +0.6% | -2.4% | -3.0% | -6.4% | -10.7% | +12.4% |
| Feb 18 | Chardan Capital | Maintains | Neutral → Neutral | — | $0.42 | $0.43 | +1.0% | -3.0% | +6.1% | -4.9% | -3.2% | +2.8% |
| Feb 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.42 | $0.43 | +1.0% | -3.0% | +6.1% | -4.9% | -3.2% | +2.8% |
| Jan 5 | Chardan Capital | Maintains | Neutral → Neutral | — | $0.66 | $0.68 | +3.5% | -17.8% | -2.4% | +11.4% | +2.4% | -2.4% |
| Jan 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.58 | $0.64 | -59.4% | -58.2% | -17.8% | -2.4% | +11.4% | +2.4% |
| Dec 22 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.01 | $2.03 | +1.0% | -8.5% | +1.1% | -1.6% | -0.5% | +8.8% |
| Sep 30 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.06 | $1.08 | +1.9% | +0.0% | -1.9% | +2.9% | -0.9% | +2.8% |
| Sep 22 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.96 | $0.95 | -1.3% | +0.5% | +0.3% | +1.8% | -1.5% | -0.4% |
| Aug 29 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.09 | $1.04 | -4.6% | -21.9% | +2.2% | +2.3% | -0.2% | +5.3% |
| Aug 29 | Guggenheim | Downgrade | Buy → Neutral | — | $1.09 | $1.04 | -4.6% | -21.9% | +2.2% | +2.3% | -0.2% | +5.3% |
| Aug 28 | Chardan Capital | Maintains | Neutral → Neutral | — | $2.38 | $0.79 | -66.8% | -54.2% | -21.9% | +2.2% | +2.3% | -0.2% |
| Aug 15 | Chardan Capital | Maintains | Neutral → Neutral | — | $2.43 | $2.50 | +2.9% | -3.7% | +18.4% | -5.1% | -9.1% | +0.8% |
| Jun 6 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.87 | $1.88 | +0.5% | +1.6% | +0.0% | -3.2% | -2.7% | +2.8% |
| Feb 24 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.56 | $1.56 | +0.0% | -2.6% | -2.6% | +1.4% | -8.0% | +8.7% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.87 | $1.85 | -1.1% | -8.6% | -0.6% | -3.5% | -4.9% | -2.6% |
| Feb 18 | Chardan Capital | Maintains | Neutral → Neutral | — | $1.87 | $1.85 | -1.1% | -8.6% | -0.6% | -3.5% | -4.9% | -2.6% |
| Jan 17 | Guggenheim | Maintains | Buy → Buy | — | $2.19 | $2.19 | +0.0% | +1.8% | +3.1% | -9.1% | -2.4% | -2.5% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.19 | $2.19 | +0.0% | +1.8% | +3.1% | -9.1% | -2.4% | -2.5% |
| Dec 2 | Chardan Capital | Downgrade | Buy → Neutral | — | $2.05 | $2.07 | +1.0% | -1.0% | -10.8% | -8.3% | -11.4% | +3.4% |
| Nov 29 | BTIG | Maintains | Buy → Buy | — | $1.70 | $1.70 | +0.0% | +20.6% | -1.0% | -10.8% | -8.3% | -11.4% |
| Nov 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.70 | $1.70 | +0.0% | +20.6% | -1.0% | -10.8% | -8.3% | -11.4% |
| Aug 16 | Chardan Capital | Maintains | Buy → Buy | — | $7.68 | $7.57 | -1.4% | +0.4% | -7.1% | -0.8% | +2.4% | -1.4% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.34 | $7.45 | +1.5% | +4.6% | +0.4% | -7.1% | -0.8% | +2.4% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.33 | $7.34 | +0.1% | +6.1% | +2.2% | -1.0% | +1.7% | -5.9% |
| Mar 27 | BTIG | Upgrade | Neutral → Buy | — | $8.68 | $9.36 | +7.8% | +7.9% | +27.4% | -14.1% | -5.5% | -6.0% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.63 | $8.74 | +1.3% | -1.4% | +2.0% | +7.9% | +27.4% | -14.1% |
| Feb 15 | Chardan Capital | Upgrade | Neutral → Buy | — | $8.41 | $9.00 | +7.0% | +15.3% | -6.9% | -3.9% | -3.7% | +2.6% |
| Jan 25 | Guggenheim | Upgrade | Neutral → Buy | — | $8.00 | $8.72 | +9.0% | +8.8% | -0.7% | +3.4% | -7.1% | -7.0% |
| Jan 25 | Brookline Capital | Upgrade | Hold → Buy | — | $8.00 | $8.72 | +9.0% | +8.8% | -0.7% | +3.4% | -7.1% | -7.0% |
| Dec 29 | Ascendiant Capital | Maintains | Buy → Buy | — | $8.53 | $8.97 | +5.2% | -7.6% | -0.3% | +6.1% | -6.5% | -1.8% |
| Dec 27 | Capital One | Upgrade | Equal Weight → Overweight | — | $8.92 | $10.00 | +12.1% | +3.7% | -7.8% | -7.6% | -0.3% | +6.1% |
| Nov 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.80 | $6.80 | +0.0% | +25.7% | +4.7% | +13.3% | -1.4% | -11.0% |
| Aug 31 | Chardan Capital | Downgrade | Buy → Neutral | — | $5.37 | $5.07 | -5.6% | -15.1% | -0.9% | +1.8% | -3.5% | -2.5% |
| Aug 31 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $5.37 | $5.07 | -5.6% | -15.1% | -0.9% | +1.8% | -3.5% | -2.5% |
| Aug 30 | Brookline Capital | Downgrade | Buy → Hold | — | $28.20 | $5.59 | -80.2% | -81.0% | -15.1% | -0.9% | +1.8% | -3.5% |
| Aug 30 | BTIG | Downgrade | Buy → Neutral | — | $28.20 | $5.59 | -80.2% | -81.0% | -15.1% | -0.9% | +1.8% | -3.5% |
| Aug 30 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $28.20 | $5.59 | -80.2% | -81.0% | -15.1% | -0.9% | +1.8% | -3.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.40 | $32.00 | +1.9% | -1.3% | -12.3% | +4.8% | -6.7% | +3.0% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $31.40 | $32.00 | +1.9% | -1.3% | -12.3% | +4.8% | -6.7% | +3.0% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.20 | $32.00 | -0.6% | +0.6% | +1.9% | +0.6% | +4.2% | -3.5% |
| May 16 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $24.00 | $23.80 | -0.8% | -0.8% | +0.8% | +1.7% | +9.8% | +21.6% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.00 | $23.80 | -0.8% | -0.8% | +0.8% | +1.7% | +9.8% | +21.6% |
| May 16 | Chardan Capital | Maintains | Buy → Buy | — | $24.00 | $23.80 | -0.8% | -0.8% | +0.8% | +1.7% | +9.8% | +21.6% |
| May 15 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $23.00 | $23.00 | +0.0% | +4.3% | -0.8% | +0.8% | +1.7% | +9.8% |
| Apr 3 | Guggenheim | Maintains | Buy → Buy | — | $21.80 | $22.20 | +1.8% | -1.8% | -4.7% | +0.0% | +1.0% | +1.0% |
| Feb 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.80 | $24.00 | +0.8% | -2.5% | -3.4% | -0.9% | +4.5% | +0.0% |
| Feb 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $23.00 | $23.80 | +3.5% | +9.6% | +0.8% | +0.0% | +0.8% | -2.3% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.60 | $21.00 | +1.9% | +1.9% | +0.0% | +1.9% | +0.9% | +15.7% |
| Oct 31 | BTIG | Maintains | Buy → Buy | — | $23.90 | $25.00 | +4.6% | -2.9% | -0.9% | -9.6% | +2.9% | +0.0% |
| Sep 13 | Chardan Capital | Maintains | Buy → Buy | — | $22.40 | $23.20 | +3.6% | +5.4% | -2.5% | +0.0% | +2.6% | +6.8% |
No insider trades available.
8-K · 8.01
!! High
Outlook Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Outlook Therapeutics raised capital through a registered direct offering of common stock and a concurrent private placement of warrants to purchase 16.1 million shares, expanding its equity base.
Apr 23
8-K · 8.01
!! High
Outlook Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Outlook Therapeutics met with the FDA to appeal a complete response letter for its ONS-5010 wet AMD treatment, potentially moving toward regulatory approval after the December rejection.
Apr 21
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Outlook Therapeutics escalated an FDA disagreement over its bevacizumab biosimilar LYTENAVA through formal dispute resolution, signaling potential regulatory impasse that could delay commercialization and threaten shareholder value.
Apr 7
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
OTLK issued warrants at $0.25 exercise price expiring in five years, allowing investors cheap upside exposure if the stock appreciates significantly from current levels.
Mar 25
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Outlook Therapeutics secured a material partnership with Atlas Sciences, potentially expanding its commercial reach or product pipeline, which could accelerate revenue growth and reduce execution risk for shareholders.
Mar 16
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Outlook Therapeutics' executive change effective March 10, 2026, could signal leadership transition risks or strategic repositioning that investors should monitor for potential impacts on R&D direction and pipeline execution.
Mar 11
8-K
Unknown — 8-K Filing
Shareholders approved KPMG as auditor and supported executive compensation, indicating stable governance and investor confidence in management's pay structure at Outlook Therapeutics.
Mar 10
8-K · 8.01
!! High
Outlook Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Outlook Therapeutics held a Type A meeting with the FDA to address deficiencies in its wet AMD drug ONS-5010, following a December 2025 complete response letter rejection of the biologics license application.
Mar 5
8-K
Outlook Therapeutics, Inc. -- 8-K Filing
Outlook Therapeutics notified Nasdaq it will attempt to cure a listing deficiency during a compliance period, potentially through a reverse stock split, or face delisting if unsuccessful.
Feb 18
8-K
Outlook Therapeutics, Inc. -- 8-K Filing
Outlook Therapeutics is expanding LYTENAVA's European presence with Austrian launch completed and additional markets planned, while advancing ONS-5010 through FDA engagement to strengthen its pipeline.
Feb 17
8-K · 8.01
!! High
Outlook Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Outlook Therapeutics requested an FDA Type A meeting to address deficiencies in its ONS-5010 wet AMD treatment application, signaling continued regulatory engagement despite the December complete response letter.
Feb 11
Data updated apr 26, 2026 6:08pm
· Source: massive.com